Changes this week
Changes detected in the 7 days to Nov 21, 2026
- Notable: REGN5381 · Heart Failure With Reduced Ejection Fraction Results posted: Nov 19, 2026
- Notable: Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells · Multiple Myeloma Undergoing Autologous Stem Cell Transplant Results posted: Nov 19, 2026
- Notable: Oral ZL-65 Tablets in Healthy and Obese · Cardiovascular Risk Eligibility criteria changed
- Notable: ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration Start date pushed from Jul 13, 2018 to Jan 30, 2019
- Notable: Performance of the Next-Generation SAFESYNC Transcatheter Heart Valve · Severe Aortic Stenosis Enrollment increased: 40 → 210 participants
- Notable: Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin Eligibility criteria changed
- Notable: Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers Start date pushed from Nov 23, 2026 to Jan 19, 2027
- Notable: Baricitinib · Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis Eligibility criteria changed
- Notable: H1ssF-3928 mRNA-LNP in Healthy Adults Results posted: Nov 19, 2026
- Notable: FESS With or Without Intranasal Desmopressin in Chronic Rhinosinusitis With Nasal Polyps Start date pushed from Oct 15, 2026 to Jan 15, 2027
- Notable: Type O Whole Blood and Assessment of Age During Prehospital Resuscitation Trial Results posted: Nov 19, 2026
- Notable: EFFET - Study of Executive Functions Regarding the Usability and User Experience of Assistive Technologies Among the Elderly Start date pushed from Oct 1, 2026 to Jan 15, 2027
- Notable: High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN) Primary completion date changed from estimate of Sep 30, 2021 to Jan 30, 2025
- Notable: Telephone Delivered Weight Loss, Nutrition, Exercise WeLNES Study Results posted: Nov 19, 2026
- Notable: CEUS Evaluation of Hydrocephalus in Neonates and Infants Start date pushed from Nov 30, 2026 to Dec 30, 2026
- Notable: PEP-CMV Vaccine Targeting CMV Antigen · Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma Eligibility criteria changed
- Notable: MRI Study of OnabotulinumtoxinA (OnabotA) Effect on Jaw Muscle Pain Start date pushed from Oct 2026 to Dec 1, 2026
- Notable: Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile® Start date pushed from Oct 2026 to Dec 2026
- Notable: Rectus Sheath Block for Analgesia After Gynecological Laparotomy Results posted: Nov 19, 2026
- Notable: Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas Enrollment increased: 39 → 84 participants
- Notable: Identify Genes/Pathways Responsible for Progression From Low Risk to Higher Risk Prostate Cancer Primary completion moved earlier from Jul 31, 2030 to Jul 31, 2028
- Notable: Qi Gong Program on Dissociative Symptoms · Experienced Childhood Trauma Start date pushed from Sep 2026 to Dec 2026
- Notable: Acute Myocardial Infarction in Cancer Patients Study completion date changed from estimate of Dec 31, 2025 to Nov 17, 2026
- Notable: Predictive Algorithms for Critical Rehabilitation Outcomes Enrollment increased: 250 → 390 participants
- Notable: COG+OT Telerehabilitation · Subjective Cognitive Complaints Start date pushed from Nov 1, 2026 to Dec 2026
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates